AU2003297356A1 - Prevention and treatment of cardiac arrhythmias - Google Patents

Prevention and treatment of cardiac arrhythmias

Info

Publication number
AU2003297356A1
AU2003297356A1 AU2003297356A AU2003297356A AU2003297356A1 AU 2003297356 A1 AU2003297356 A1 AU 2003297356A1 AU 2003297356 A AU2003297356 A AU 2003297356A AU 2003297356 A AU2003297356 A AU 2003297356A AU 2003297356 A1 AU2003297356 A1 AU 2003297356A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
cardiac arrhythmias
arrhythmias
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003297356A
Other versions
AU2003297356A8 (en
Inventor
Alain D. Baron
David R. Hathaway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of AU2003297356A1 publication Critical patent/AU2003297356A1/en
Publication of AU2003297356A8 publication Critical patent/AU2003297356A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2003297356A 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias Abandoned AU2003297356A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43450802P 2002-12-17 2002-12-17
US60/434,508 2002-12-17
US43488802P 2002-12-19 2002-12-19
US60/434,888 2002-12-19
PCT/US2003/040504 WO2004056313A2 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Publications (2)

Publication Number Publication Date
AU2003297356A1 true AU2003297356A1 (en) 2004-07-14
AU2003297356A8 AU2003297356A8 (en) 2004-07-14

Family

ID=32685317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003297356A Abandoned AU2003297356A1 (en) 2002-12-17 2003-12-17 Prevention and treatment of cardiac arrhythmias

Country Status (4)

Country Link
EP (1) EP1610811A4 (en)
JP (1) JP2006514035A (en)
AU (1) AU2003297356A1 (en)
WO (1) WO2004056313A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016027157A1 (en) 2014-08-21 2016-02-25 Daphot Enterprises Limited Peptide for treatment of type 2 diabetes mellitus and its complications

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555894A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EA011653B1 (en) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Gip analog and hybrid polypeptides with selectable properties
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
CN101296942A (en) * 2005-08-11 2008-10-29 安米林药品公司 Hybrid polypeptides with selectable properties
AU2007267833B2 (en) * 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
AU2008306190A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of bubuc and optionally EAA-MART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
PT2373681T (en) 2008-12-10 2017-04-11 Glaxosmithkline Llc Pharmaceutical compositions of albiglutide
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2771025A1 (en) * 2011-10-28 2014-09-03 Pharis Biotec GmbH A polypeptide for the protection against heart ischemia-reperfusion injury
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
JP2016503771A (en) 2012-12-21 2016-02-08 サノフイ Exendin-4 derivative
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
WO2019038412A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN108939052B (en) * 2018-09-04 2021-03-16 江苏省中医药研究院 Application of exenatide in preparation of medicine for preventing or treating atrial fibrillation
CN110551203B (en) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 Exenatide analogue
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
AU759058C (en) * 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
KR100518046B1 (en) * 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Treatment of acute coronary syndrome with glp-1
ATE470448T1 (en) * 2000-10-20 2010-06-15 Amylin Pharmaceuticals Inc TREATMENT OF HYPOACTIVE MYOCARDIAL AND DIABETIC CARDIAC MYOPATHY WITH A GLP-1 PEPTIDE
WO2002085406A1 (en) * 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016027157A1 (en) 2014-08-21 2016-02-25 Daphot Enterprises Limited Peptide for treatment of type 2 diabetes mellitus and its complications
US9868773B2 (en) 2014-08-21 2018-01-16 Daphot Enterprises Limited Peptide for treatment of type 2 diabetes mellitus and its complications

Also Published As

Publication number Publication date
EP1610811A4 (en) 2008-03-26
EP1610811A2 (en) 2006-01-04
JP2006514035A (en) 2006-04-27
WO2004056313A2 (en) 2004-07-08
AU2003297356A8 (en) 2004-07-14
WO2004056313A3 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AU2003297356A1 (en) Prevention and treatment of cardiac arrhythmias
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU2001245767A1 (en) Continuous localization and guided treatment of cardiac arrhythmias
AU5032500A (en) Treatment of irregular ventricular contractions
AU2003229923A1 (en) Curcumin for the prevention and/or treatment of tissue damage
AU2003296379A1 (en) Methods and devices for cardiac surgery
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
AU2002357830A1 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2003287354A1 (en) An intracardiac catheter and method of use
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2003268295A1 (en) "diagnosis and treatment of infertility"
EP1765832B8 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
AU2003233681A1 (en) Diagnosis and treatment of human dormancy syndrome
AU2003268923A1 (en) Treatment of aml
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003231279A1 (en) Prevention and treatment of type 2 diabetes
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2003270815A1 (en) Treatment of irritable bowel syndrome and related bowel diseases
AU2003219880A1 (en) Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
AU2003297282A1 (en) Protection of cardiac myocardium
AU2002952129A0 (en) Treatment of hypersensitivity conditions
AU2003207315A1 (en) Treatment of muscle damage

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase